

Claims

1. A pharmaceutical composition for enhancement of adiponectin production comprising as an active ingredient one or more HMG-CoA reductase inhibitor(s).
2. A pharmaceutical composition according to claim 1, wherein the HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, pitavastatin and rosuvastatin.
3. A pharmaceutical composition according to claim 1, wherein the HMG-CoA reductase inhibitor is a water-soluble HMG-CoA reductase inhibitor.
4. A pharmaceutical composition according to claim 1, wherein the HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin or a derivative thereof and rosuvastatin or a derivative thereof.
5. A pharmaceutical composition according to claim 1, wherein the HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin.
6. A pharmaceutical composition according to claim 1, wherein the HMG-CoA reductase inhibitor is pravastatin.
7. A pharmaceutical composition for the treatment or prevention of hypoadiponectinemia comprising as an active ingredient one or more water-soluble HMG-CoA reductase inhibitor(s).
8. A pharmaceutical composition according to claim 7, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin or a derivative thereof and rosuvastatin or a derivative thereof.
9. A pharmaceutical composition according to claim 7, wherein the water-soluble HMG-CoA reductase inhibitor is a

medicament selected from the group consisting of pravastatin and rosuvastatin.

10. A pharmaceutical composition according to claim 7, wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin.

11. A pharmaceutical composition for improving insulin resistance comprising as an active ingredient one or more water-soluble HMG-CoA reductase inhibitor(s).

12. A pharmaceutical composition according to claim 11, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin or a derivative thereof and rosuvastatin or a derivative thereof.

13. A pharmaceutical composition according to claim 11, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin.

14. A pharmaceutical composition according to claim 11, wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin.

15. A pharmaceutical composition for the treatment or prevention of Syndrome X or metabolic syndrome comprising as an active ingredient one or more HMG-CoA reductase inhibitor(s).

16. A pharmaceutical composition according to claim 15, wherein the HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, pitavastatin and rosuvastatin.

17. A pharmaceutical composition according to claim 15, wherein the HMG-CoA reductase inhibitor is a water-soluble HMG-CoA reductase inhibitor.

18. A pharmaceutical composition according to claim 15, wherein the HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin or a derivative thereof and rosuvastatin or a derivative thereof.
19. A pharmaceutical composition according to claim 15, wherein the HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin.
20. A pharmaceutical composition according to claim 15, wherein the HMG-CoA reductase inhibitor is pravastatin.
21. A pharmaceutical composition for the treatment or prevention of hypertension comprising as an active ingredient one or more water-soluble HMG-CoA reductase inhibitor(s).
22. A pharmaceutical composition according to claim 21, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin or a derivative thereof and rosuvastatin or a derivative thereof.
23. A pharmaceutical composition according to claim 21, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin.
24. A pharmaceutical composition according to claim 21, wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin.
25. A pharmaceutical composition for the treatment or prevention of obesity comprising as an active ingredient one or more water-soluble HMG-CoA reductase inhibitor(s).
26. A pharmaceutical composition according to claim 25, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of

pravastatin or a derivative thereof and rosuvastatin or a derivative thereof.

27. A pharmaceutical composition according to claim 25, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin.

28. A pharmaceutical composition according to claim 25, wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin.

29. A pharmaceutical composition for the treatment of arteriosclerosis comprising as an active ingredient one or more water-soluble HMG-CoA reductase inhibitor(s).

30. A pharmaceutical composition according to claim 29, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin or a derivative thereof and rosuvastatin or a derivative thereof.

31. A pharmaceutical composition according to claim 29, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin.

32. A pharmaceutical composition according to claim 29, wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin.

33. A pharmaceutical composition for the treatment or prevention of diabetes, diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease), hypertension, obesity or arteriosclerosis caused by hypoadiponectinemia, comprising as an active ingredient one or more water-soluble HMG-CoA reductase inhibitor(s).

34. A pharmaceutical composition according to claim 33, wherein the water-soluble HMG-CoA reductase inhibitor is a

medicament selected from the group consisting of pravastatin or a derivative thereof and rosuvastatin or a derivative thereof.

35. A pharmaceutical composition according to claim 33, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin.

36. A pharmaceutical composition according to claim 33, wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin.

37. A pharmaceutical composition for the treatment or prevention of hypertension, obesity or arteriosclerosis caused by insulin resistance syndrome, comprising as an active ingredient one or more water-soluble HMG-CoA reductase inhibitor(s).

38. A pharmaceutical composition according to claim 37, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin or a derivative thereof and rosuvastatin or a derivative thereof.

39. A pharmaceutical composition according to claim 37, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin.

40. A pharmaceutical composition according to claim 37, wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin.

41. A method for enhancement of adiponectin production comprising administration of an effective amount of one or more HMG-CoA reductase inhibitor(s) to a warm-blooded animal.

42. A method for treatment or prevention of Syndrome X or metabolic syndrome comprising administration of an

effective amount of one or more HMG-CoA reductase inhibitor(s) to a warm-blooded animal.

43. A method according to claim 41 or 42, wherein the HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, pitavastatin and rosuvastatin.

44. A method according to claim 41 or 42, wherein the HMG-CoA reductase inhibitor is a water-soluble HMG-CoA reductase inhibitor.

45. A method according to claim 41 or 42, wherein the HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin or a derivative thereof and rosuvastatin or a derivative thereof.

46. A method according to claim 41 or 42, wherein the HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin.

47. A method according to claim 41 or 42, wherein the HMG-CoA reductase inhibitor is pravastatin.

48. A method for treatment or prevention of hypoadiponectinemia comprising administration of an effective amount of one or more water-soluble HMG-CoA reductase inhibitor(s) to a warm-blooded animal.

49. A method for improving insulin resistance comprising administration of an effective amount of one or more water-soluble HMG-CoA reductase inhibitor(s) to a warm-blooded animal.

50. A method for treatment or prevention of hypertension comprising administration of one or more water-soluble HMG-CoA reductase inhibitor(s) to a warm-blooded animal.

51. A method for treatment or prevention of obesity comprising administration of one or more water-soluble HMG-CoA reductase inhibitor(s) to a warm-blooded animal.

52. A method for treatment of arteriosclerosis comprising administration of one or more water-soluble HMG-CoA reductase inhibitor(s) to a warm-blooded animal.
53. A method for treatment or prevention of diabetes, diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease), hypertension, obesity or arteriosclerosis caused by hypoadiponectinemia comprising administration of one or more water-soluble HMG-CoA reductase inhibitor(s) to a warm-blooded animal.
54. A method for treatment or prevention of hypertension, obesity or arteriosclerosis caused by insulin resistance syndrome comprising administration of one or more water-soluble HMG-CoA reductase inhibitor(s) to a warm-blooded animal.
55. A method according to any one of claims 48 to 54, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin.
56. A method according to any one of claims 48 to 54, wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin.
57. A method according to any one of claims 41 to 56, wherein the warm-blooded animal is a human.